Article Text

other Versions

PDF
Vaccination against influenza in rheumatoid arthritis patients: the effect of rituximab on the humoral response
  1. Shirly Oren (orenim{at}hotmail.com)
  1. Tel Aviv Medical Center, Israel
    1. Michal Mandelboim
    1. Chaim Sheba Medical Center, Israel
      1. Yolanda Braun-Moscovici
      1. Rambam Health Care Center, Israel
        1. Daphna Paran
        1. Tel Aviv Medical Center, Israel
          1. Jacob Ablin
          1. Tel Aviv Medical Center, Israel
            1. Irena Litinsky
            1. Tel Aviv Medical Center, Israel
              1. David Levartovsky
              1. Tel Aviv Medical Center, Israel
                1. Doron Comaneshter
                1. Tel Aviv Medical Center, Israel
                  1. Ella Mendelson
                  1. Chaim Sheba Medical Center, Israel
                    1. Roberto Azar
                    1. Chaim Sheba Medical Center, Israel
                      1. Irena Wigler
                      1. Tel Aviv Medical Center, Israel
                        1. Alexandra Balbir-Gurman
                        1. Rambam Health Care Center, Israel
                          1. Dan Caspi
                          1. Tel Aviv Medical Center, Israel
                            1. Ori Elkayam (oribe14{at}netvision.net.il)
                            1. Tel Aviv Medical Center, Israel

                              Abstract

                              Objective: To assess the effect of rituximab on the efficacy and safety of influenza virus vaccine in patients with rheumatoid arthritis (RA).

                              Methods: The study population comprised RA patients treated with conventional disease modifying drugs with or without rituximab. Split-virion inactivated vaccine containing 15 mcg hemagglutinin/dose of B/Shanghai/361/02 (SHAN), A/New Caledonia A/New Caledonia/ 20/99 (NC) (H1N1) and A/California/7/04 (CAL) (H3N2) was used. Disease activity was assessed by number of tender and swollen joints, morning stiffness duration, and evaluation of pain on the day of vaccination and 4 weeks later. CD19 positive cell levels were assessed in rituximab treated patients. Hemagglutination inhibition (HI) antibodies were tested and response was defined as >4-fold rise 4 weeks post vaccination or seroconversion in patients with a non-protective baseline level of antibodies (<1/40). Geometric mean titers (GMT) were calculated in all subjects.

                              Results: The participants were divided into 3 groups: RA (n=29, aged 64±12 years), rituximab-treated RA (n=14, aged 53±15 years) and healthy controls (n=21, aged 58±15 years). All baseline protective levels of HI antibodies and GMT were similar. Four weeks after vaccination, there was a significant increase in GMT for NC and California antigens in all subjects, but not for the Shanghai antigen in the rituximab group. In Rituximab treated patients,, the percentage of responders was low for all three antigens tested, achieving statistical significance for California antigen. Parameters of disease activity remained unchanged.

                              Conclusion: Influenza virus vaccine generated a humoral response in all RA study patients and controls. Although the response was significantly lower among rituximab-treated patients, treatment with rituximab does not preclude administration of vaccination against influenza.

                              • influenza
                              • response
                              • rheumatoid
                              • rituximab

                              Statistics from Altmetric.com

                              Request permissions

                              If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.